PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23916555-0 2013 PXR-ALAS1: a key regulatory pathway in liver toxicity induced by isoniazid-rifampicin antituberculosis treatment. Isoniazid 65-74 nuclear receptor subfamily 1 group I member 2 Homo sapiens 0-3 32387752-3 2020 Rifampicin and isoniazid co-therapy targets porphyrin biosynthesis via PXR and results in hepatic protoporphyrin IX accumulation and subsequent liver injury. Isoniazid 15-24 nuclear receptor subfamily 1 group I member 2 Homo sapiens 71-74 32660103-0 2020 Toxicoproteomic Profiling of hPXR Transgenic Mice Treated with Rifampicin and Isoniazid. Isoniazid 78-87 nuclear receptor subfamily 1 group I member 2 Homo sapiens 29-33 32660103-5 2020 To elucidate the mechanism of rifampicin- and isoniazid-induced liver and systemic injury, we performed tandem mass tag mass spectrometry-based proteomic screening of mPxr-/- and hPXR mice treated with combinations of rifampicin and isoniazid. Isoniazid 46-55 nuclear receptor subfamily 1 group I member 2 Homo sapiens 179-183 23475203-0 2013 Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Isoniazid 66-75 nuclear receptor subfamily 1 group I member 2 Homo sapiens 6-9 30779340-7 2019 In this exploratory study in Ugandan patients coinfected with HIV/TB, genetic variants in PXR, SLCO1B1, and NAT2 were moderately associated with isoniazid exposure, whereas PXR 63396TT carriers showed worse outcomes. Isoniazid 145-154 nuclear receptor subfamily 1 group I member 2 Homo sapiens 90-93 30779340-7 2019 In this exploratory study in Ugandan patients coinfected with HIV/TB, genetic variants in PXR, SLCO1B1, and NAT2 were moderately associated with isoniazid exposure, whereas PXR 63396TT carriers showed worse outcomes. Isoniazid 145-154 nuclear receptor subfamily 1 group I member 2 Homo sapiens 173-176